Following our previous findings that iNOS- and/or TNF-α-expressing slanMo are detectable in tissue specimens of patients with various inflammatory disorders (35, 36, 46), we investigated whether nRCT modulates the percentage of iNOS- or TNF-α-producing slanMo in matched pre-nRCT and post-nRCT tumor specimens of 10 patients. Here, TNF is linked to neoplasm.